A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy

Michelle De Graaf, Tapio J. Nevalainen, Hans W. Scheeren, Herbert M. Pinedo, Hidde J. Haisma, Epie Boven

Research output: Contribution to journalArticle

Abstract

The glucuronide prodrug of doxorubicin, DOX-GA3, can be selectively activated in tumors by extracellular human β-glucuronidase, resulting in a better therapeutic index than doxorubicin. DOX-GA3, however, is rapidly excreted by the kidney. We hypothesized that slow release of DOX-GA3 from its methylester, DOX-mGA3, by esterase activity in blood would result in improved circulation half-life (t 1/2) of DOX-GA3. DOX-mGA3 was synthesized more efficiently with an overall yield of 60% as compared to 37% in the case of DOX-GA3. We showed that DOX-mGA3 was enzymatically converted to DOX-GA3 with a t 1/2 of approximately 0.5 min in mouse plasma to 2.5 h in human plasma, which was in agreement with differences in esterase activity between species. DOX-mGA3, similar to DOX-GA3, was at least 37-fold less potent than the parent drug doxorubicin in growth inhibition of four different human malignant cell lines in vitro. Incubation of OVCAR-3 cells with DOX-mGA3 in combination with an excess of human β-glucuronidase (0.05 U mL -1) resulted in a similar growth inhibition to that of doxorubicin. Intravenous administration of DOX-mGA3 in FMa-bearing mice resulted in an area under the concentration versus time curve (AUC) of DOX-GA3 in tumor and most normal tissues that was 2.5- to 3-fold higher than after the same dose of DOX-GA3 itself. In tumor tissue, this was accompanied by a 2.7-fold increase in the AUC of doxorubicin from DOX-mGA3 than from DOX-GA3. In conclusion, an advantage of DOX-mGA3 over DOX-GA3 is that this prodrug can be produced with a higher yield. Another important advantage is the improved pharmacokinetics of the lipophilic DOX-mGA3 as compared to that of the hydrophilic DOX-GA3. This effect may even be more pronounced in man, because of the lower plasma esterase activity than measured in mice.

Original languageEnglish (US)
Pages (from-to)2273-2281
Number of pages9
JournalBiochemical Pharmacology
Volume68
Issue number11
DOIs
StatePublished - Dec 1 2004
Externally publishedYes

Fingerprint

Chemotherapy
Glucuronides
Prodrugs
Tumors
Drug Therapy
Neoplasms
Doxorubicin
Esterases
Glucuronidase
Area Under Curve
N-(4-doxorubicin-N-carbonyl(oxymethyl)phenyl)-O-glucuronyl carbamate
Bearings (structural)
Tissue
Plasma (human)
Plasmas
Pharmacokinetics
Growth
Intravenous Administration
Half-Life
Blood

Keywords

  • β-Glucuronidase
  • Cancer chemotherapy
  • Doxorubicin
  • Esterases
  • Glucuronide
  • Prodrug

ASJC Scopus subject areas

  • Pharmacology

Cite this

Graaf, M. D., Nevalainen, T. J., Scheeren, H. W., Pinedo, H. M., Haisma, H. J., & Boven, E. (2004). A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. Biochemical Pharmacology, 68(11), 2273-2281. https://doi.org/10.1016/j.bcp.2004.08.004

A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. / Graaf, Michelle De; Nevalainen, Tapio J.; Scheeren, Hans W.; Pinedo, Herbert M.; Haisma, Hidde J.; Boven, Epie.

In: Biochemical Pharmacology, Vol. 68, No. 11, 01.12.2004, p. 2273-2281.

Research output: Contribution to journalArticle

Graaf, MD, Nevalainen, TJ, Scheeren, HW, Pinedo, HM, Haisma, HJ & Boven, E 2004, 'A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy', Biochemical Pharmacology, vol. 68, no. 11, pp. 2273-2281. https://doi.org/10.1016/j.bcp.2004.08.004
Graaf, Michelle De ; Nevalainen, Tapio J. ; Scheeren, Hans W. ; Pinedo, Herbert M. ; Haisma, Hidde J. ; Boven, Epie. / A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy. In: Biochemical Pharmacology. 2004 ; Vol. 68, No. 11. pp. 2273-2281.
@article{0063dda37bd44aeabdcf453b8588c888,
title = "A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy",
abstract = "The glucuronide prodrug of doxorubicin, DOX-GA3, can be selectively activated in tumors by extracellular human β-glucuronidase, resulting in a better therapeutic index than doxorubicin. DOX-GA3, however, is rapidly excreted by the kidney. We hypothesized that slow release of DOX-GA3 from its methylester, DOX-mGA3, by esterase activity in blood would result in improved circulation half-life (t 1/2) of DOX-GA3. DOX-mGA3 was synthesized more efficiently with an overall yield of 60{\%} as compared to 37{\%} in the case of DOX-GA3. We showed that DOX-mGA3 was enzymatically converted to DOX-GA3 with a t 1/2 of approximately 0.5 min in mouse plasma to 2.5 h in human plasma, which was in agreement with differences in esterase activity between species. DOX-mGA3, similar to DOX-GA3, was at least 37-fold less potent than the parent drug doxorubicin in growth inhibition of four different human malignant cell lines in vitro. Incubation of OVCAR-3 cells with DOX-mGA3 in combination with an excess of human β-glucuronidase (0.05 U mL -1) resulted in a similar growth inhibition to that of doxorubicin. Intravenous administration of DOX-mGA3 in FMa-bearing mice resulted in an area under the concentration versus time curve (AUC) of DOX-GA3 in tumor and most normal tissues that was 2.5- to 3-fold higher than after the same dose of DOX-GA3 itself. In tumor tissue, this was accompanied by a 2.7-fold increase in the AUC of doxorubicin from DOX-mGA3 than from DOX-GA3. In conclusion, an advantage of DOX-mGA3 over DOX-GA3 is that this prodrug can be produced with a higher yield. Another important advantage is the improved pharmacokinetics of the lipophilic DOX-mGA3 as compared to that of the hydrophilic DOX-GA3. This effect may even be more pronounced in man, because of the lower plasma esterase activity than measured in mice.",
keywords = "β-Glucuronidase, Cancer chemotherapy, Doxorubicin, Esterases, Glucuronide, Prodrug",
author = "Graaf, {Michelle De} and Nevalainen, {Tapio J.} and Scheeren, {Hans W.} and Pinedo, {Herbert M.} and Haisma, {Hidde J.} and Epie Boven",
year = "2004",
month = "12",
day = "1",
doi = "10.1016/j.bcp.2004.08.004",
language = "English (US)",
volume = "68",
pages = "2273--2281",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - A methylester of the glucuronide prodrug DOX-GA3 for improvement of tumor-selective chemotherapy

AU - Graaf, Michelle De

AU - Nevalainen, Tapio J.

AU - Scheeren, Hans W.

AU - Pinedo, Herbert M.

AU - Haisma, Hidde J.

AU - Boven, Epie

PY - 2004/12/1

Y1 - 2004/12/1

N2 - The glucuronide prodrug of doxorubicin, DOX-GA3, can be selectively activated in tumors by extracellular human β-glucuronidase, resulting in a better therapeutic index than doxorubicin. DOX-GA3, however, is rapidly excreted by the kidney. We hypothesized that slow release of DOX-GA3 from its methylester, DOX-mGA3, by esterase activity in blood would result in improved circulation half-life (t 1/2) of DOX-GA3. DOX-mGA3 was synthesized more efficiently with an overall yield of 60% as compared to 37% in the case of DOX-GA3. We showed that DOX-mGA3 was enzymatically converted to DOX-GA3 with a t 1/2 of approximately 0.5 min in mouse plasma to 2.5 h in human plasma, which was in agreement with differences in esterase activity between species. DOX-mGA3, similar to DOX-GA3, was at least 37-fold less potent than the parent drug doxorubicin in growth inhibition of four different human malignant cell lines in vitro. Incubation of OVCAR-3 cells with DOX-mGA3 in combination with an excess of human β-glucuronidase (0.05 U mL -1) resulted in a similar growth inhibition to that of doxorubicin. Intravenous administration of DOX-mGA3 in FMa-bearing mice resulted in an area under the concentration versus time curve (AUC) of DOX-GA3 in tumor and most normal tissues that was 2.5- to 3-fold higher than after the same dose of DOX-GA3 itself. In tumor tissue, this was accompanied by a 2.7-fold increase in the AUC of doxorubicin from DOX-mGA3 than from DOX-GA3. In conclusion, an advantage of DOX-mGA3 over DOX-GA3 is that this prodrug can be produced with a higher yield. Another important advantage is the improved pharmacokinetics of the lipophilic DOX-mGA3 as compared to that of the hydrophilic DOX-GA3. This effect may even be more pronounced in man, because of the lower plasma esterase activity than measured in mice.

AB - The glucuronide prodrug of doxorubicin, DOX-GA3, can be selectively activated in tumors by extracellular human β-glucuronidase, resulting in a better therapeutic index than doxorubicin. DOX-GA3, however, is rapidly excreted by the kidney. We hypothesized that slow release of DOX-GA3 from its methylester, DOX-mGA3, by esterase activity in blood would result in improved circulation half-life (t 1/2) of DOX-GA3. DOX-mGA3 was synthesized more efficiently with an overall yield of 60% as compared to 37% in the case of DOX-GA3. We showed that DOX-mGA3 was enzymatically converted to DOX-GA3 with a t 1/2 of approximately 0.5 min in mouse plasma to 2.5 h in human plasma, which was in agreement with differences in esterase activity between species. DOX-mGA3, similar to DOX-GA3, was at least 37-fold less potent than the parent drug doxorubicin in growth inhibition of four different human malignant cell lines in vitro. Incubation of OVCAR-3 cells with DOX-mGA3 in combination with an excess of human β-glucuronidase (0.05 U mL -1) resulted in a similar growth inhibition to that of doxorubicin. Intravenous administration of DOX-mGA3 in FMa-bearing mice resulted in an area under the concentration versus time curve (AUC) of DOX-GA3 in tumor and most normal tissues that was 2.5- to 3-fold higher than after the same dose of DOX-GA3 itself. In tumor tissue, this was accompanied by a 2.7-fold increase in the AUC of doxorubicin from DOX-mGA3 than from DOX-GA3. In conclusion, an advantage of DOX-mGA3 over DOX-GA3 is that this prodrug can be produced with a higher yield. Another important advantage is the improved pharmacokinetics of the lipophilic DOX-mGA3 as compared to that of the hydrophilic DOX-GA3. This effect may even be more pronounced in man, because of the lower plasma esterase activity than measured in mice.

KW - β-Glucuronidase

KW - Cancer chemotherapy

KW - Doxorubicin

KW - Esterases

KW - Glucuronide

KW - Prodrug

UR - http://www.scopus.com/inward/record.url?scp=7444241374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444241374&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2004.08.004

DO - 10.1016/j.bcp.2004.08.004

M3 - Article

VL - 68

SP - 2273

EP - 2281

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 11

ER -